Abdullah Karakus , Ugur Hatipoglu , Yavuz Katircilar , Mehmet Ali Erkurt , Seda Yilmaz , Gulsum Akgun Cagliyan , Fahir Ozturk , Emine Hidayet , Sinan Demircioglu , Mustafa Koroglu , Ant Uzay , Abdulkadir Basturk , Suleyman Sami Karti , Ahmet Sarici , Servihan Unal , Mehmet Sinan Dal , Turgay Ulaş , Serdal Korkmaz , Fevzi Altuntas
{"title":"The comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma","authors":"Abdullah Karakus , Ugur Hatipoglu , Yavuz Katircilar , Mehmet Ali Erkurt , Seda Yilmaz , Gulsum Akgun Cagliyan , Fahir Ozturk , Emine Hidayet , Sinan Demircioglu , Mustafa Koroglu , Ant Uzay , Abdulkadir Basturk , Suleyman Sami Karti , Ahmet Sarici , Servihan Unal , Mehmet Sinan Dal , Turgay Ulaş , Serdal Korkmaz , Fevzi Altuntas","doi":"10.1016/j.transci.2025.104183","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>We conducted a multi-center retrospective non-randomized study to clarify roles of 2 and 3 gr/m<sup>2</sup> doses of Cyclophosphamide (Cy) for stem cell mobilization in Multiple Myeloma.</div></div><div><h3>Material and methods</h3><div>This study analyzed 169 adult patients who received Cy-based mobilization regimen at doses 2 and 3 gr/m<sup>2</sup> between 2018 and 2024. All patients included in this study were 18 years old and older. Patients divided into two groups; group 1 represents 2 gr/m<sup>2</sup> treated patients, and group 2 represents 3 gr/m<sup>2</sup> dosing. These two groups then compared in terms of CD34<sup>+</sup> cell number collected by apheresis, apheresis days, peak peripheral blood CD34<sup>+</sup> value and rates of mobilization failures.</div></div><div><h3>Results</h3><div>Higher doses of Cy yielded more hematopoietic stem cells compared to the lower dose Cy [10.00 (3.00–28.90) vs 9.01 (5.00–14.90), p = 0.002]; while mobilization failures and apheresis days were comparable across groups (p = 0.112 and p = 0.648, respectively). Apheresis days required for adequate stem cell harvest among groups was found statistically similar (p = 0.648).</div></div><div><h3>Conclusion</h3><div>This study indicated the superior efficacy of 3 gr/m<sup>2</sup> dose of Cy in terms of stem cell yield. However, mobilization failure and prolonged apheresis sessions were not issues with lower doses.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104183"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion and Apheresis Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S147305022500120X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
We conducted a multi-center retrospective non-randomized study to clarify roles of 2 and 3 gr/m2 doses of Cyclophosphamide (Cy) for stem cell mobilization in Multiple Myeloma.
Material and methods
This study analyzed 169 adult patients who received Cy-based mobilization regimen at doses 2 and 3 gr/m2 between 2018 and 2024. All patients included in this study were 18 years old and older. Patients divided into two groups; group 1 represents 2 gr/m2 treated patients, and group 2 represents 3 gr/m2 dosing. These two groups then compared in terms of CD34+ cell number collected by apheresis, apheresis days, peak peripheral blood CD34+ value and rates of mobilization failures.
Results
Higher doses of Cy yielded more hematopoietic stem cells compared to the lower dose Cy [10.00 (3.00–28.90) vs 9.01 (5.00–14.90), p = 0.002]; while mobilization failures and apheresis days were comparable across groups (p = 0.112 and p = 0.648, respectively). Apheresis days required for adequate stem cell harvest among groups was found statistically similar (p = 0.648).
Conclusion
This study indicated the superior efficacy of 3 gr/m2 dose of Cy in terms of stem cell yield. However, mobilization failure and prolonged apheresis sessions were not issues with lower doses.
期刊介绍:
Transfusion and Apheresis Science brings comprehensive and up-to-date information to physicians and health care professionals involved in the rapidly changing fields of transfusion medicine, hemostasis and apheresis. The journal presents original articles relating to scientific and clinical studies in the areas of immunohematology, transfusion practice, bleeding and thrombotic disorders and both therapeutic and donor apheresis including hematopoietic stem cells. Topics covered include the collection and processing of blood, compatibility testing and guidelines for the use of blood products, as well as screening for and transmission of blood-borne diseases. All areas of apheresis - therapeutic and collection - are also addressed. We would like to specifically encourage allied health professionals in this area to submit manuscripts that relate to improved patient and donor care, technical aspects and educational issues.
Transfusion and Apheresis Science features a "Theme" section which includes, in each issue, a group of papers designed to review a specific topic of current importance in transfusion and hemostasis for the discussion of topical issues specific to apheresis and focuses on the operators'' viewpoint. Another section is "What''s Happening" which provides informal reporting of activities in the field. In addition, brief case reports and Letters to the Editor, as well as reviews of meetings and events of general interest, and a listing of recent patents make the journal a complete source of information for practitioners of transfusion, hemostasis and apheresis science. Immediate dissemination of important information is ensured by the commitment of Transfusion and Apheresis Science to rapid publication of both symposia and submitted papers.